An Israeli chemical manufacturing company has developed a new coupling reagent in peptide synthesis, for use in the pharmaceutical industry. Main advantages over those on the market include non-toxic and non-allergic properties, safety for producer and user, no limitation in transporting, universality in solvents, compatibility with microwave heating etc. The company is looking for commercial agency, distribution services and licensing agreements for cooperation.
The Israeli company develops and manufactures products to address the needs of peptide synthesis process. Many peptides cannot be obtained without involvement of special compounds – the so-called coupling reagents. The latters activate two initial substances forcing a chemical reaction to occur with creation of the needed peptide. The company develops and manufactures these coupling reagents. Usually these are rather active (aggressive) substances that are harmful to the environment. The company constantly does its best to develop the substances that are less harmful or even have no negative effects at all.
One of the developed substances is the offered coupling reagent. It is registered under the trademark, obtained by the company’s developed technology. The product has a lot of advantages as compared to those existing on the market for the same use (see advantages). The product appeared to be the pH modulatory agent in prevention from base driven side reactions and its effect on 2-chlorotrityl chloride resin.
Highly polar nature of the product influences on its water solubility, which is essential to remove the coupling byproducts in solution-based acylations. On the other hand, the great solubility of the product in organic solvents has prompted its use in evaluation of green alternatives to DMF (dimethylformamide). The offered product is important as compatible with microwave heating. The company’s proprietary products are designed to provide maximum yield of peptides with necessary quality. The company works under the most rigorous quality assurance standards available. Their products are applied in a wide range of fields, including peptide, oligonucleotide and nanoparticle synthesis. Their developed methods ensure safer products of smaller ecological footprint.
The company was established in 2008 and created by the bigger company, because its activity had grown to such extent that it could not remain one of the departments. It was essential to convert the biotech direction into a company. Nowadays the company strives to preserve and protect the environment and to consider the outcomes of their industrial field, in order to make more efficient, safe, worthwhile and eco-friendly industry. Because of rather far location from its customers (pharma companies) in EU (e.g, France, Italy, Germany, Spain), the company is willing to get closer to its clients. So, they got interested in partnership with European companies through representatives, distributors of their products, companies who would get licensed to sell and assist in application of the company products to new customers, too.
The company is looking for partnership with trade and industrial (CMO-contract manufacturing organization or CDMO-contract developing and manufacturing organisations) enterprises familiar with needs of pharmaceutical companies. The cooperation could be in the frame of commercial agency (an agent represents the
company products and abilities), distribution services (a partner sells the company products) and license agreements (a partner becomes a licensee) for cooperation.
- Specific area of activity of the partner: -TYPE - industry, business, trade
-ACTIVITY - distributor / agent / representative (companies) with experience / knowledge in manufacturing and trade of pharmaceutical intermediates and active pharmaceutic ingredients; might be contract manufacturing organisations(CMO) or contract developing and manufacturing organisations (CDMO) active in pharmaceutics
-ROLE - under commercial agency or distribution services agreement – it is expected that a partner finds local pharmaceutic companies, which would : 1)use the offered reagent in their peptide synthesis processes and 2)produce for pharmaceutical companies using the products offered,
-under license agreement – it is expected that a partner would represent the company interests and sell / buy products abroad.
The developed technology has resulted in the innovative product allowing the following advantages:
1.Ability to achieve a free-of-salts product (of more than 99.5% purity) and to control the ratio “active / non-active” substance.
2.Approval as being non-toxic and non-allergic.
3.Less risk of explosion and flammability than existing products used for the same purposes (safety to producer and user).
4.No limitation for land, sea and air transportation.
5.Excellent replacement for those on the market and other analogues (without change of protocol).
6.The results in step-wise solid phase synthesis are comparable to those of existing products, but with less epimerization in the fragment condensation reactions.
7.The best balance between reactivity and stability.
8. The product is universal - highly soluble in a broad spectrum of solvents.
9.Compatibility with microwave heating, etc.
Seleccione una de las siguientes opciones para interesarse por esta oportunidad: